Concise Prescribing Info
Bronchitis, community acquired pneumonia, sinusitis, pharyngitis/tonsillitis, otitis media, skin & soft tissue infections, uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrhea.
Dosage/Direction for Use
Adult, childn >45 kg, the elderly 1,500 mg given over 3 days (500 mg once daily). Uncomplicated Chlamydia trachomatis 1,000 mg as a single dose. Neisseria gonorrhea 1,000 mg or 2,000 mg in combination w/ 250 mg or 500 mg ceftriaxone.
Should be taken on an empty stomach.
Hypersensitivity to azithromycin, erythromycin or any macrolide or ketolide antibiotic.
Special Precautions
Rare serious allergic reactions including angioneurotic oedema & anaphylaxis (rarely fatal). Precipitated ergotism in concomitant use w/ ergotamine derivatives; patients w/ increased risk for prolonged cardiac repolarisation; congenital or documented acquired QT prolongation; currently treatment w/ other active substances known to prolong QT interval, eg antiarrhythmics class IA & III, cisapride & terfenadine; electrolyte disturbance, particularly hypokalemia & hypomagnesaemia; bradycardia, cardiac arrhythmia or severe cardiac insufficiency. Clostridium difficile associated diarrhoea may occur. Exacerbations of myasthenia gravis symptoms & new onset of myasthenia gravis. Observe for signs & superinfection w/ non-susceptible organisms including fungi. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption. May affect ability to drive or operate machinery. 33% increased systemic exposure in patients w/ severe renal impairment (GFR <10 mL/min). Patients w/ significant hepatic disease; fulminant hepatitis potentially leading to life-threatening hepatic failure; perform hepatic function tests/investigations w/ occurrence of signs & symptoms eg, rapid asthenia development associated w/ jaundice, dark urine, bleeding tendency or hepatic encephalopathy. Pregnancy & lactation (discontinue breastfeeding during treatment until 2 days after discontinuation of treatment).
Adverse Reactions
Diarrhoea, abdominal pain, nausea, flatulence. Decreased lymphocyte count, increased eosinophil count; anorexia; dizziness, headache, paraesthesia, dysgeusia; visual impairment; deafness; vomiting, dyspepsia; rash, pruritus; arthralgia; fatigue; decreased blood bicarbonate.
Drug Interactions
Approx 24% reduction in peak serum conc w/ antacids. Increased conc w/ nelfinavir. Potential risk of neutropenia w/ rifabutin. Not recommended w/ ergotamine alkaloids for risk of ergotism. Increased levels of digoxin. Potentiated anticoagulation subsequent to co-administration w/ coumarin-type oral anticoagulants; frequently monitor prothrombin time. Monitor cyclosporin levels for elevated Cmax & AUC. Increased conc of phosphorylated zidovudine (zidovudine active metabolite).
MIMS Class
ATC Classification
J01FA10 - azithromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
Ziomycin FC tab 250 mg
1 × 6's;10 × 6's
Ziomycin FC tab 500 mg
1 × 3's;10 × 3's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in